Highlights Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Real-time Estimate Cboe BZX Other stock markets 01:05:22 2024-06-10 pm EDT			5-day change	1st Jan Change
0.311 ^USD	-2.93%		-4.46%	-94.08%

May. 21	Lyra Therapeutics Reduces Workforce to Extend Cash Runway	MT
May. 21	Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell	May. 06	MT
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study	May. 06	DJ
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	May. 06	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	23-09-12	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Lyra Therapeutics Jumps Premarket Following Insider Share Purchases	23-06-05	MT
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Lyra Therapeutics, Inc. Announces Commencement of Enrollment in ENLIGHTEN II	23-04-25	CI
LYRA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-29	AQ
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients	23-02-06	CI
LYRA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-08	AQ
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
LYRA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)	22-11-02	AQ
Lyra Therapeutics Inc. Advances Phase 2 Beacon Clinical Trial of Lyr-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study	22-09-13	CI
Lyra Therapeutics, Inc. Announces New LYR-210 data analyses from the Phase 2 LANTERN study	22-09-10	CI
Lyra Therapeutics Announces First Patient Enrolled in Pivotal Enlighten II Clinical Trial of Lyr-210 in Chronic Rhinosinusitis Patients	22-09-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Highlights

Filters